Understand the source comparison
GHRP-2 Acetate vs Other Growth Hormone Secretagogues: Research Comparison
Growth hormone secretagogues represent multiple structural classes with distinct pharmacology. This comparison focuses on the peptide secretagogues most commonly used in research. GHRP-2, GHRP-6, ipamorelin, hexarelin, and the non-peptide secretagogue MK-677.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth hormone secretagogues represent multiple structural classes with distinct pharmacology. This comparison focuses on the peptide secretagogues most commonly used in research. GHRP-2, GHRP-6, ipamorelin, hexarelin, and the non-peptide secretagogue MK-677. Highlighting receptor selectivity, GH response amplitude, side effect profiles, and experimental use cases.
- GHRP-2 Acetate
- GHS-R1a agonist
- 8–12× in rats at 10 mcg/kg
- 20–30 minutes
- Reliable dose-response, well-characterized synergy with GHRH, minimal desensitization
- Moderate cortisol and prolactin co-secretion at doses >20 mcg/kg
- Gold standard for GH secretion profiling. Extensive literature base, predictable pharmacology, and reproducible results across labs
- GHRP-6
- 10–15× in rats at 10 mcg/kg
- 15–20 minutes
- Strongest appetite stimulation (orexigenic effect via hypothalamic ghrelin pathways), useful for metabolic studies
- Significant appetite increase limits use in weight-sensitive protocols
- Best for studies explicitly examining ghrelin's orexigenic signaling. Avoid in protocols where food intake is a confounding variable
- Ipamorelin
- GHS-R1a selective agonist
- 5–8× in rats at 10 mcg/kg
- 2–3 hours
- Minimal cortisol/prolactin co-secretion, most selective for GH release
- Lower peak GH amplitude, shorter commercial availability history
- Preferred for long-duration studies where cortisol elevation would confound metabolic or stress-related outcomes
- Hexarelin
- 15–20× in rats at 10 mcg/kg
- 60–90 minutes
- Highest GH response amplitude, cardioprotective effects independent of GH
- Rapid receptor desensitization (50% response loss after 7–10 days daily dosing)
- Use for acute GH response studies or cardioprotection research. Not suitable for sustained multi-week GH elevation protocols
- MK 677 (Ibutamoren)
- GHS-R1a agonist (non-peptide)
- 2–4× sustained elevation in humans
- 4–6 hours (oral bioavailability)
- Orally active, sustained GH elevation without injections
- Water retention, appetite increase, potential insulin resistance with chronic use
- Best for studies requiring oral administration or sustained multi-day GH elevation. Peptides deliver sharper pulses for acute profiling
- The choice depends on research objectives. For pulsatile GH secretion profiling, GHRP-2 and hexarelin produce the highest-amplitude pulses. GHRP-2 wins for reproducibility across repeated doses. For metabolic studies where cortisol confounds interpretation, ipamorelin's selectivity is essential. For studies explicitly examining ghrelin's appetite effects, GHRP-6 is the only compound where orexigenic signaling is strong enough to measure behaviorally. For sustained multi-day GH elevation without injections, MK-677 is the only viable option despite lower peak amplitude.
- Synergy with GHRH analogues like CJC1295 Ipamorelin or Sermorelin is well-documented for GHRP-2, GHRP-6, and ipamorelin. All three produce 2.5–3.5× greater GH release when co-administered with GHRH compared to either compound alone. Hexarelin shows weaker synergy due to its already-maximal receptor activation.